MBZUAI's Eduardo da Veiga Beltrame is developing machine learning tools for analyzing single-cell RNA sequencing data, which measures RNA in thousands of individual cells. Sequencing costs have decreased faster than Moore's Law, enabling large-scale data collection in biology. RNA sequencing provides insights into gene expression and cellular activity, crucial for personalized medicine. Why it matters: Advancements in single-cell RNA sequencing and ML analysis will accelerate personalized medicine by providing detailed insights into cellular mechanisms and disease pathways.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
KAUST and King Faisal Specialist Hospital and Research Centre (KFSHRC) are collaborating to develop an RNA sequencing tool to improve the diagnosis rate of genetic diseases. The tool analyzes RNA data to find aberrant transcripts and mutations, building on KFSHRC's clinical data and KAUST's computational expertise. The team has already solved cases that DNA sequencing alone could not, including a case of a young child with brain damage caused by a recessive gene mutation. Why it matters: This collaboration can improve disease management and preventative services in the region, directly contributing to Saudi Arabia’s national research priority of health and wellness.
Khaled Alsayegh at the King Abdullah International Medical Research Center is creating a Saudi Stem Cell Donor Registry, with 80,000 potential donors identified. The aim is to identify universal donors, reprogram their cells into induced pluripotent stem (iPS) cells, and create a gene bank for matched tissue transplants. Alsayegh is collaborating with Jesper Tegnér at KAUST to create pacemaker cells using single-cell RNA sequencing. Why it matters: This initiative could revolutionize precision medicine in KSA by providing readily available, matched cells for transplants, reducing the need for patient-specific reprogramming and improving treatment outcomes.
MBZUAI's Assistant Professor of Computational Biology, Eduardo Beltrame, is researching single-cell RNA sequencing to advance personalized medicine. He is also designing MBZUAI’s new master’s and Ph.D. programs in computational biology, set to launch in 2026, under the guidance of Professor Eran Segal. MBZUAI's research agenda includes foundational initiatives like AIDO and the Human Phenotype Project, leveraging vast datasets such as the Emirati Genome Project. Why it matters: This highlights MBZUAI's commitment to cutting-edge research and education in computational biology, positioning it as a potential rival to top global institutions in the field.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.